R&D The diagnostic odyssey: Challenges and opportunities in tran... Transthyretin amyloidosis (ATTR) is a rarely diagnosed and relentless disease that demands our attention.
R&D When costing and compliance collide Only a few years ago, compliance was the undisputed top priority in the pharmaceutical industry - regardless of cost.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
R&D Looking to early-stage companies for innovation, with Juerge... In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
R&D BIO 2025: Healey shades Trump as she announces $40M in tax i... Massachusetts Governor Maura Healey took shots at the Trump Administration as she announced $40M in life sciences tax incentives at BIO 2025.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
